Delta-fly Pharma, Inc.

Otsuka Pharmaceutical Factory, Inc.

Kyoto University

Taiho Pharmaceutical Company Limited

Hiromi Wada

Tatsuhiro Ishida

Shinichi Matsumoto

Kiyoshi Eshima

Hirofumi Noguchi

Cheng Long Huang

Takayuki Nakamura

Koichi Tanaka

Harubumi Kato

Takaaki Koshiba

Xiangdong Zhao

Mitsuo Ohta

Yukito Ichinose

Masahiro Tsuboi

Reo Hamaguchi

Cheng-Long Huang

An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

Urine alkali agent useful for treatment of cancer patient

The present invention relates to a pharmaceutical composition comprising a citrate salt for use in enhancing the effect of an anticancer drug.

Anticancer drug effect enhancer

The present application provides a pharmaceutical composition for use in treatment or remission of patients with chronic myelogenous leukemia, wherein the composition comprises, as active ingredients, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, and 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide or a pharmacologically acceptable salt thereof, both of which are used at low doses.

Pharmaceutical composition for treatment or remission of chronic myelogenous leukemia

An object of the present invention is to provide a novel treatment method with fewer side effects for elderly cancer patients and terminal cancer patients. A pharmaceutical composition for treating or putting an elderly or a terminal cancer patient into remission, comprising, as an active ingredient, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof.

Pharmaceutical composition for treatment of or remission in elderly or terminal cancer patient

The present invention provides a pancreatic islet isolation method comprising the steps of (1) injecting a protection solution containing a protease inhibitor into the pancreatic duct of an procured pancreas; (3) digesting the pancreas into which the protection solution has been injected; and (4) purifying the digested pancreatic tissue using a purification solution containing a density gradient reagent. The present invention also provides a protection solution for injection into the pancreatic duct, a pancreas preservation solution for the two-layer method, and an islet purification solution.

Method of separating pancreatic islet

This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3' end.

Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof

This invention provides a novel RNAi molecule that can significantly potentiate antitumor effects of a 5-FU antitumor agent. The RNAi molecule comprises the nucleotide sequence shown in SEQ ID NO: 2. The invention also provides an antitumor agent comprising such RNAi molecule and a 5-FU antitumor agent.

RNAi molecule targeting thymidylate synthase and application thereof

The present invention provides a liver preservation solution containing trehalose and dibutyryl-cAMP. The content of nitroglycerin in the preservation solution is preferably lower than 0.44 mM. In the liver preservation solution of the present invention, since the toxicity due to nitroglycerin, which is observed during liver preservation, has been improved, liver transplantation can be performed with a high engrafted rate.

Method for preserving liver in a solution comprising dibutyryl cAMP

The present invention provides an improved method for treating lung cancer, preferably non-small cell lung cancer, by orally administering UFT to postoperative lung cancer patients.

Growing community of inventors

Kyoto, Japan

Hiromi Wada